See the DrugPatentWatch profile for Epclusa
Is there a generic version of Epclusa (sofosbuvir/velpatasvir) yet?
Epclusa is the brand name for a fixed-dose hepatitis C treatment containing sofosbuvir + velpatasvir. Whether a “generic Epclusa” exists depends on patent and exclusivity status for the specific products used in each country/market.
If you’re trying to confirm availability in a particular country (for example, the US vs. EU vs. India), share your location and I can narrow it down.
What does “Epclusa generica” usually mean in practice?
People searching “Epclusa generica” often mean one of these:
- A true generic tablet made under patent rules (same active ingredients, similar dosing).
- A branded “authorized generic” from the same manufacturer of the original product.
- An unbranded or “copy” product marketed by a third party (which may or may not be fully authorized in a given country).
To avoid mix-ups, it helps to check the active ingredients (sofosbuvir + velpatasvir), strength, and whether the product is approved/authorized locally.
When do generics typically enter for Epclusa?
Generic entry timing is driven by patent expiration and regulatory exclusivity, which can differ by market. Patent-watch resources track these timelines and related litigation, including for Epclusa’s patents covering sofosbuvir/velpatasvir combinations. DrugPatentWatch.com is commonly used for this kind of check: https://www.drugpatentwatch.com/ (search “Epclusa” there). 1
How can I check whether a generic is approved where I live?
Look for:
- The local medicines regulator’s approval page (drug database).
- The exact drug name and strength list (sofosbuvir/velpatasvir).
- Marketing authorization holder and product labeling that matches approved formulations.
If you tell me your country, I can point you to the most relevant regulator/authorization database approach.
Can I switch from Epclusa to a generic for hepatitis C?
Switching is usually about ensuring the alternative product is approved and bioequivalent (same active ingredients, comparable exposure). For hepatitis C cure regimens, small formulation differences can matter, so patients should switch only under a prescriber’s guidance and ideally using an approved product.
Sources